# Immunization Service Provider Call

# **April 2023**

Please place your name, and provider in the chat.

**OKLAHOMA** State Department of Health



# Agenda

- State Data / COVID Administration Guidance
- COVID-19 Vaccine Ordering Update
- Vaccine Storage and Handling
- Vaccine Ordering & Distribution
- OSIIS Updates
- Guest Speaker
- Lauren Speer, BSN, RN., Nursing Services
  - Reducing Vaccine Errors
- Looking Forward

# COVID-19 Vaccine State Data & Administration Guidance

Rishu Garg, Adult Vaccine Coordinator



# COVID-19 VACCINATIONS IN OKLAHOMA – FEDERAL AND STATE (AS OF 3/30/2023)

2,957,861 people have received at least 1 dose\* of the COVID-19 vaccine



2,396,612 people are fully vaccinated\*\* with the COVID-19 vaccine

998,552 people have received a 3rd dose<sup>^</sup> or booster dose<sup>^</sup> of the COVID-19 vaccine  $\mathbf{x}$ 

364,654 people have received a 4<sup>th</sup> dose or 2<sup>nd</sup> booster dose of the COVID-19 vaccine

469,545 people have received the bivalent booster dose of the COVID-19 vaccine

 $\mathbf{>>}$ 



Across Oklahoma, a total of 6,752,460 COVID-19 vaccine doses have been administered since 12/14/2020


\*Refers to eligible individuals receiving Pfizer and Moderna COVID-19 vaccines and/or receiving single shot of J&J/Janssen Vaccine; \*\*Refers to eligible individuals (ages 5 years +) fully vaccinated after receiving either Pfizer and/or Moderna COVID-19 vaccines (both doses) and/or receiving single shot of J&J/Janssen Vaccine; ^3rd dose (Pfizer or Moderna) for individuals moderately to severely immunocompromised to be received at least 28 days after a second dose; ^ Booster dose for individuals 65+ or certain other adults at high risk of severe COVID-19 to be received at least six months after completion of the primary mRNA vaccine series or two months after receiving single dose of J&J/Janssen vaccine.

Not for public distribution, data intended for internal planning purposes.

Data Source: CDC COVID Data Tracker - Tiberius Database. Data as of: March 29, 2023 6:00am ET. Posted: March 30, 2023


### COVID-19 Vaccination Schedule Infographic for People who are NOT Moderately or Severely Immunocompromised

### People ages 6 months through 4 years




### People age 5 years







#### People ages 6 through 11 years



#### People ages 12 years and older



#### People ages 18 years and older who previously received Janssen primary series dose<sup>§</sup>



\*People ages 6m-4yrs who previously completed a 3-dose monovalent Pfizer-BioNTech primary series are authorized to receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of monovalent primary series.

### Clinical Guidance for COVID-19 Vaccination | CDC

**Covid-19 Vaccination** 

Immunocompromised)

**Schedule** 

(Non-

#### 5

# **Covid-19 Vaccination Schedule**


# (Immunocompromised)




### Clinical Guidance for COVID-19 Vaccination | CDC


### COVID-19 Vaccination Schedule Infographic for People who ARE Moderately or Severely Immunocompromised

### People ages 6 months through 4 years




### People age 5 years







#### People ages 6 through 11 years



### People ages 12 years and older



#### People ages 18 years and older who previously received Janssen primary series dose<sup>9</sup>



\*People ages 6m-4yrs who previously completed a 3-dose monovalent Pfizer-BioNTech primary series are authorized to receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of monovalent primary series.

## Pfizer-BioNTech COVID-19 Vaccine, Primary and Bivalent Presentations 12+ Years and older

	PRIMARY SERIES ONLY		BOOSTER	OOSE ONLY						
	PFIZER-BIONTECH COVID-19 VACCINE*	Comirnaty (Covid-19 Vaccine, mrna), do not dilute:	PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT, DO NOT DILLITE <sup>1</sup>							
Age Group	12 years	and older	<b>12 years and older</b> (See additional information in teal box to the right of table)							
Vial Cap Color	Gi		Gr	ay						
Dose	30	mcg	30 mcg							
Dose Volume	0.3	mL	0.3 mL							
Amount of Diluent Needed per Vial	NO DI	UTION	NO DILUTION							
Doses per Vial	-	dose vial: s per vial	Multiple dose vial: 6 doses per vial	Single dose vial 1 dose per vial						
Ultra-Low-Temperature (ULT) Freezer [-90 °C to -60 °C (-130 °F to -76 °F)]		18 m	onths							
Freezer [-25 °C to -15 °C (-13 °F to 5 °F)]	DO NOT STORE									
Refrigerator [2 °C to 8 °C (35 °F to 46 °F)]	10 weeks									
Room Temperature [8 °C to 25 °C (46 °F to 77 °F)]	12 hours prior to first puncture (including any thaw time)									
After First Puncture [2 °C to 25 °C (35 °F to 77 °F)]		Discard af	ter 12 hours	Discard after 12 hours						

<u>COMIRNATY</u> Full Prescribing Information - 12+ Gray Cap



The complete formulation guide can be downloaded here: <u>https://webfiles.pfizer.com/formulation-guide</u> For more extensive information and guidance, including each formulation's EUA Fact Sheet: <u>https://www.cvdvaccine-us.com/</u>

## Pfizer-BioNTech COVID-19 Vaccine, Primary and Bivalent Presentations 6m-4y & 5-11 Years

		io vaconio, i initaly and	Bivalent i resentation		
	PRIMARY SERIES ONLY	BOOSTER DOSE ONLY	PRIMARY SERIES	BOOSTER DOSE ONLY*	
	PFIZER-BIONTECH COVID-19 VACCINE, DILUTE BEFORE USE®	PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT, DILUTE BEFORE USE <sup>4</sup>	PFIZER-BIONTECH COVID-19 VACCINE AND PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT, DILLUTE BEFORE USE'	PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT, DILUTE BEFORE USE <sup>4</sup>	
Age Group	5 through 11 years ("Age 5y to <12y" on vial label)	5 through 11 years ("Age 5y to <12y" on vial label) (See additional information in teal box to the right of table)	6 months through 4 years (See additional information in boxed maroon text to the right of table)	6 months through 4 years	
'ial Cap Color	Orange	Orange	Maroon	Maroon	
Dose	10 mcg	10 mcg	3 mcg	3 mcg	
lose Volume	0.2 mL	0.2 mL	0.2 mL	0.2 mL	
mount of Diluent Needed per Vial	1.3 mL	1.3 mL	2.2 mL	2.2 mL	
oses per Vial	10 doses per vial (after dilution)	10 doses per vial (after dilution)	10 doses per vial (after dilution)	10 doses per vial (after dilution)	
	Storage (	Conditions	Storage (	Conditions	
tra-Low-Temperature (ULT) Freezer 90 °C to -60 °C (-130 °F to -76 °F)]	18 mo	onthst	18 mo	onths <sup>‡</sup>	
reezer -25 °C to -15 °C (-13 °F to 5 °F)]	DO NOT	T STORE	DO NOT	STORE	
Refrigerator [2 °C to 8 °C (35 °F to 46 °F)]	10 w	veeks	10 w	eeks	
Room Temperature [8 °C to 25 °C (46 °F to 77 °F)]		or to dilution ny thaw time)	12 hours prior to dilution (including any thaw time)		
After First Puncture [2 °C to 25 °C (35 °F to 77 °F)]	Discard aft	ter 12 hours‡	Discard aft	er 12 hours	

The complete formulation guide can be downloaded here: <a href="https://webfiles.pfizer.com/formulation-guide">https://webfiles.pfizer.com/formulation-guide</a> For more extensive information and guidance, including each formulation's EUA Fact Sheet: <a href="https://www.cvdvaccine-us.com/">https://www.cvdvaccine-us.com/</a>

## **Moderna COVID-19 Vaccine Presentations**

		Moderna COVID-19 Vaccin (Primary Series Doses)	Moderna COVID-19 Vaccine, Bivalent (Booster Dose)			
Age Group	6 months through 5 years of age	6 years through 11 years of age	12 years of age and older <sup>‡</sup>	6 months through 5 years of age	6 years of age and older	
Doses Per Vial	10 doses	5 doses	Maximum of 11 doses (range: 10-11 doses)	2 doses <sup>∞</sup>	5-10 doses†	
Volume per Dose	0.25 mL	0.25 mL 0.5 mL		0.2 mL	For 6 years through 11 years: 0.25 ml For 12 years of age and older: 0.5 mL	
Vial label and NDC	Magenta Border	Purple Border*	Light Blue Border	Here CANDE -19 Hander Here CANDE -19 Hander	Gray Border	
Carton and NDC	NDC 80777-279-99	NDC 80777-275-99	NDC 80777-273-99	NDC 80777-283-99	NDC 80777-282-99	



\*Moderna COVID-19 Vaccine, Bivalent is authorized as a booster dose in individuals 6 months through 5 years of age at least 2 months after completing the Moderna COVID-19 Vaccine primary series. Moderna COVID-19 Vaccine, Bivalent is authorized as a booster dose in individuals 6 years of age and older at least 2 months after any authorized or approved vaccine. † The Moderna COVID-19 Vaccine vial labeled "BOOSTER DOSES ONLY" is authorized to provide Primary Series Doses (0.5 mL each) for individuals 6 through 11 years of age.

### For more information, please see the FDA-Authorized Fact Sheets: Moderna COVID-19 FDA Fact Sheets

## FDA Covid-Vaccine Updates as of 3.29.23

- On March 14<sup>th</sup>, the FDA amended the EUA of the <u>Pfizer-BioNTech COVID-19 Vaccine</u>, Bivalent to provide for a single booster dose of the vaccine in children 6 months through 4 years of age at least 2 months after completion of primary vaccination with three doses of the monovalent Pfizer-BioNTech COVID-19 Vaccine.
  - NOTE: The original monovalent Pfizer-BioNTech COVID-19 Vaccine was previously but is no longer authorized for use as the third dose of the primary series in individuals 6 months through 4 years of age.
  - <u>More Detailed Information Provided Here</u>
- Additional updates include:

FDA revised the Janssen COVID-19 Vaccine Fact Sheet for Healthcare Providers Administering Vaccine as well as the scope of authorization for a booster dose of the Janssen COVID-19 Vaccine to reflect that the vaccine may be administered as a first booster dose at least 2 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine. Learn More Here

FDA posted a revised Moderna COVID-19 Vaccine Presentations Wall Chart

# **Additional Vaccine Updates**

## **Moderna**

- Moderna Monovalent 12+ and 6-11 formulations have expired with no anticipated expiration extension.
  - Orders for these products to support primary series vaccinations are no longer accepted.
  - Pfizer (12+ and 5-11) and Novavax (12+) monovalent vaccines remain available for ordering for primary series vaccination.
    - There is an ample supply of both products, and providers can order additional supply.
  - Providers should be aware that depending on the date of the first administered Moderna dose, the same product may not be available to complete the primary series.
    - In this case, a different COVID-19 vaccine may be administered to complete the primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose.
      - > Please read <u>CDC guidance</u> on interchanging COVID-19 vaccines for more information.

## <u>Novavax</u>

- Ordering of the 10-dose vial presentation of Novavax COVID-19 vaccine (Unit of Sale NDC: 80631-0100-10) has closed.
  - All viable doses of Novavax currently in the field have an expiration date of April 30, 2023 with no anticipated expiration extension.
- Ordering of the 5-dose vial presentation of Novavax COVID-19 vaccine (Unit of Sale NDC: 80631-0102-10) has now begun.
  - Each carton contains ten 5-dose vials with a minimum order quantity of 100 doses (2 cartons)
    - This number of doses matches the number of doses supported by existing ancillary kits. You may still opt-out of receiving ancillary kits.
    - The expiration date of this new Novavax presentation is October 31, 2023.

# Novavax

# **Dosage and Administration<sup>1</sup>**

## Dosing and schedule

- Primary Series (12 years of age and older): Administered intramuscularly as a primary series of two doses (0.5 mL each) 3 weeks apart
- First Booster Dose (18 years of age and older): Administered intramuscularly as a first booster dose (0.5mL) at least 6 months after completion of primary vaccination

- with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine





### Expiration dates can be obtained using the Novavax Expiry Date Checker

## Interchangeability of COVID-19 vaccine products

### **Primary Series**

- The CDC does not recommend mixing products for your primary series doses; mixed primary series composed of any combinations of Moderna, Novavax, and Pfizer vaccines is not authorized. All COVID-19 vaccine primary series doses should be from the same manufacturer.
- The same monovalent vaccine product should be used for all doses in the primary series with the following exception: children ages 6 months-4 years who received
   2 primary series doses of a monovalent Pfizer-BioNTech vaccine should receive a bivalent Pfizer-BioNTech vaccine as their third primary series dose.
- Children ages 6 months—4 years who received 1 monovalent Moderna vaccine and 1 monovalent Pfizer-BioNTech vaccine for the first 2 doses of a primary series should follow a <u>3-dose schedule</u>

### **Booster Vaccination**

- Bivalent mRNA vaccines are recommended. Any homologous or heterologous bivalent mRNA vaccine can be used as authorized by FDA for a given age group and product
- For people who receive a mixed primary series, booster recommendations are as follows:
  - Children ages 6 months-4 years:
    - Who receive a mixed 3-dose primary series with any combination of monovalent Moderna and monovalent Pfizer-BioNTech vaccines should receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of the primary series.
    - Who receive a mixed 3-dose primary series with a bivalent Pfizer-BioNTech vaccine as the third primary series dose should receive 1 bivalent Pfizer-BioNTech booster dose when they turn age 5 years and at least 2 months after completion of the primary series.
- Children age 5 years who receive a mixed primary series should receive 1 bivalent Pfizer-BioNTech vaccine booster dose at least 2 months after completion of the primary series.
- People ages 6 years and older who receive a mixed primary series should receive 1 mRNA booster dose (Moderna or Pfizer-BioNTech) at least 2 months after completion of the mixed monovalent primary series.



## More information on the interchangeability of COVID-19 vaccine products for children and adolescents can be found here.

# COVID- 19 Vaccine Ordering Updates





# COVID-19 Vaccines available in OSIIS

- OSIIS offers 11 Covid-19 vaccines across all age groups.
- If you wish to order less than the minimum required dose amount, please specify the number of doses you would like to order under the clinic comments before submitting the order.
- Providers do have the option to opt-out of receiving ancillary kits with some COVID-19 Vaccine Orders.
  - Please note that Pfizer Pediatric vaccines orders *cannot* OPT-OUT from receiving ancillary kits.
  - If the "opt-out" option is greyed out on the OSIIS order page for any other vaccines, but you would like to opt-out from receiving them, please indicate this request in the clinic comments.

# COVID-19 Vaccines available in OSIIS (cont.)

CVX	Name on OSIIS ordering page	NDC	Manufacturer	Minimum doses for direct-ship	Age Group	Ancillary Opt-Out	Primary or Booster
211	Novavax COVID-19 (10 x 2.5mL Multi-Dose Vial)	80631-0102-10	NOVAVAX, INC	100	12+	YES	PRIMARY ONLY
217	Pfizer Comirnaty COVID-19 (MDV6; 10 pack)	00069-2025-10	PFIZER, INC.	180	12+	YES	PRIMARY ONLY
218	COVID-19 Pfizer 5-11Yrs (10X10 (0.2mL/dose) MDV)	59267-1055-04	PFIZER, INC.	100	5Y-11Y	NO, DUE TO DILUENT	PRIMARY ONLY
219	PFR COVID Tris-suc 6m-4y (10 x 10(0.2mL/dose) MDV)	59267-0078-04	PFIZER, INC.	100	6M-4Y	NO, DUE TO DILUENT	PRIMARY ONLY
228	Moderna COVID-19 Ped 6mo - 5yr (10 x 2.5mL Vials)	80777-0279-99	MODERNA	100	6M-5Y	YES	PRIMARY ONLY
229	COV-19 (Moderna); Bivalent; MDV5	80777-0282-99	MODERNA	100	12+	YES*	BOOSTER ONLY
230	MOD COVID-19 Bivalent Bstr 6m-5y (10 x 0.40mL MDV)	80777-0283-99	MODERNA	100	6Y-12Y	YES*	BOOSTER ONLY
300	PFR COVID-19 Bivalent Bstr 12+yrs (10x2.0mL MDV)	59267-0304-02	PFIZER, INC.	180	12+	YES*	BOOSTER ONLY
300	PFR COVID-19 Bivalent Bstr 12+yrs (10x2.0mL SDV)	59267-1404-02	PFIZER, INC.	50	12+	YES*	BOOSTER ONLY
301	Pfizer COVID-19 Booster 5-11 yrs (10 x 2.0mL MDV)	59267-0565-02	PFIZER, INC.	100	5Y-11Y	NO, DUE TO DILUENT	BOOSTER ONLY
302	Pfizer COVID-19 BIV Booster 6m-4y (10 x 2.6mL MDV)	59267-0609-02	PFIZER, INC.	100	6M-4Y	NO, DUE TO DILUENT	BOOSTER ONLY

\*If you wish to opt-out from receiving ancillary kits with the order, please specify it under the clinic comments before submitting the order.


# Vaccine Storage and Handling





# **Best Practice for Inventory Management**

- To reduce waste, providers should be aware of vaccines in their inventory that are nearing expiration dates and prioritize their administration.
- Providers should enroll in the CDC Code Management Service to access the most up-to-date Expiration Information for all Vaccines.
  - <u>Vaccine Lot Number and Expiration Date Webpage</u>
  - Click the "Register" button in the upper right-hand corner to complete the registration form to request access.
- Moderna, Novavax, Pfizer, J&J Vaccine Expiration Lookup & Reference Information:
  - Moderna Vial Expiration Data Look Up Tool
  - J&J Expiration Date Look Up Tool
  - Pfizer-BioNTech Covid-19 Lot Expiry Tool
    - Novavax Expiry Date Checker Tool



# Inventory Update Required Vaccine Finder, OSIIS

# Failure to maintain an updated inventory may impact vaccine orders.

- Per the CDC, starting May 1<sup>st</sup> providers are required to update inventory in Vaccine Finder on a weekly basis.
- Inventory will be listed by vaccine name and age designation, *not* cap color.
- Training Videos and Guides:
  - https://www.vaccines.gov/covid-provider-resources/
- Step By Step Instructions:
  - <u>https://www.vaccines.gov/resources/QSG.for.Add.Vaccine.Flow\_Clean\_0</u>
     <u>6\_04\_21\_FINAL.pdf</u>
  - For assistance in updating Vaccine Finder or OSIIS please call Immunization Services at (405) 426-8580.

## **Find COVID-19 Vaccines**

Powered by VaccineFinder

5-digit Zip Code

Zip Code

### Show COVID-19 Vaccines and Boosters

Pfizer-BioNTech (age 5-11)

Pfizer-BioNTech (age 12+)

Moderna (age 18+)

Johnson & Johnson/Janssen (age 18+)

View key details about which vaccine you should get

### Show Only Locations That

Have appointments available

### Search for COVID-19 Vaccines

I'm looking for flu vaccines  $\rightarrow$ 

# **Novavax Storage and Handling**

## Unpunctured Vial

- Store the unpunctured multi-dose vaccine vial in a refrigerator between 2° to 8°C (36° to 46°F).
- Do not freeze.
- Protect from light.

## After first needle puncture of the vial

- Store the multi-dose vial between 2 to 25°C (36 to 77°F) for up to 6 hours.
  - Does not contain a preservative
- Discard any remaining vaccine that is not used within 6 hours after the first puncture.



### Additional Storage and Handling Information can be accessed here

## Pfizer Storage and Handling

Vial cap color	Monovalent Maroon Cap	Bivalent Maroon Cap	Monovalent	Bivalent Orange Cap	Monovalent	Bivalent Gray Cap				
Ages	6 months th	rough 4 years	5 throug	h 11 years	12 years	and older				
Supplied in:	MDV*: 10 doses per vial <b>Requires</b>	MDV <sup>*</sup> : 6 doses per vial SDV <sup>*</sup> : 1 dose								
	diluent	Requires diluent	Requires diluent	Requires diluent	<b>O</b> No diluent	Udiluent				
Storage Temperature: Before Puncture Do NOT store vaccine in a standard freezer	2°C and 8°C (36°F NOTE: The beyon	<b>Between:</b> -90°C and -60°C (-130°F and -76°F) until the expiration date <sup>†</sup> 2°C and 8°C (36°F and 46°F) for up to 10 weeks <b>NOTE:</b> The beyond-use date (10 weeks) replaces the manufacturer's expiration date but NEVER extends it. Always use the earliest date. Do NOT use vaccine if the expiration date or beyond-use date has passed.								
Thawing Frozen Vaccine Do NOT refreeze thawed vaccine	OR Up to 25°C (77°F)	2°C and 8°C (36°F and 46°F) OR								
Storage Temperature: After 1st Puncture Do NOT use after 12 hours	<b>Between:</b> 2°C and 25°C (36°F and 77°F) for up to 12 hours. Discard vial and any unused vaccine after 12 hours.									

Pfizer Expiry Lookup Tool

## Moderna COVID-19 Vaccine Storage and Handling

Vial cap color	Monovalent Blue capped vials with magenta- bordered label	Bivalent Pink capped vials with yellow-bordered label	Monovalent Blue capped vial with purple- bordered label	Monovalent Red capped vial with blue- bordered label	Bivalent Dark blue capped vial with gray- bordered label				
Supplied in multidose vial			5 doses per vial	10 primary doses	6 through 11 years of age: 10 doses per vial 12 years of age and older: 5 doses per vial				
Storage Temperature: Before Puncture Do NOT store vaccine in an ultra cold freezer.	2°C and 8°C (36°F and 8°C and 25°C (46° and <b>NOTE:</b> The beyond-us	<ul> <li>Between:</li> <li>-50°C and -15°C (-58°F and 5°F) until the expiration date</li> <li>2°C and 8°C (36°F and 46°F) for up to 30 days</li> <li>8°C and 25°C (46° and 77°F) for a total of 24 hours. Discard vial and unused vaccine after 24 hours.</li> <li>NOTE: The beyond-use date (30 days) replaces the manufacturer's expiration date but NEVER extends it. Always use the earliest date. Do NOT use vaccine if the expiration date or beyond-use date has passed.</li> </ul>							
Thawing Frozen Vaccine Do NOT refreeze thawed vaccine.	Between: 2°C and 8°C (36°F and 46°F) OR 15°C and 25°C (46°F and 77°F) Amount of time needed to thaw vaccine varies based on temperature and number of vials.								
Storage Temperature: After 1st Puncture Do NOT use after beyond- use date times.	<ul> <li>Between:</li> <li>2°C and 25°C (36°F and 77°F) for up to:</li> <li>8 hours - bivalent vaccine for ages 6 months through 5 years (pink capped with yellow bordered label)</li> <li>12 hours - all other Moderna COVID-19 vaccine products</li> <li>Discard vial and any unused vaccine after these time frames.</li> </ul>								

# Vaccine Ordering and Distribution






# Reconciliation

## **Reconciliation – weekly**

- Providers are required to reconcile their inventory once during the ordering time frame: **Tuesday through Monday.**
- If a clinic does not reconcile COVID inventory for 7 days, they will not be able to create a vaccine order.
- An informational video on COVID 19 vaccine reconciliation and ordering can be accessed at <u>https://vimeo.com/528424790</u>
- Inventory Reconciliation





# **Ordering Process**

- Providers can create orders in OSIIS during the ordering timeframe which is **Tuesday through Monday**.
- Vaccines can be ordered based on the need. If less than the minimum quantity is needed, providers will need to place an
  order for the minimum quantity and add a comment in the Clinic Comments indicating the number of doses needed.
- Providers now have the option to opt-out from receiving vaccine ancillary kits with their vaccine order. This doesn't apply for Pediatric Pfizer and Pediatric Pfizer Bivalent booster.
  - If you wish to opt-out, please specify this information in the Clinic Comments.
- Please do not refuse any vaccine shipments.

inic Comments												
ONLY N	EED 30	DOSES OF MODE	RNA									
evx		Name		NDC	0	Manufacturer   Code	Manufacturer	Cost per Package	Doses     Packa		Ancillary Kit	Qty of Packages
CVX	٩	NAME	Q	NDC	٩	MANUFA Q	MANUFA Q					
207		Moderna COVID-19 5.0 mL MDV)	(10 x 10 dose	80777-02	73-99	MOD	MODERNA	\$1.00	100	ADULT	v YES v	1



# **Ordering Process**

- The cut-off to create orders in OSIIS Monday, 5pm.
- To make any changes or cancellations to orders after the deadline, providers must reach out ASAP.
  - To request a change, a provider should email to OSDH VaccineHelp <<u>VaccineHelp@health.ok.gov</u>>
  - If provider doesn't receive a confirmation of changes/cancellation within 24h, provider must call the OSDH Immunization Service 405.426.8580 to ensure that the order has been cancelled.
- Orders with at least min quantity, will be approved in OSIIS and directly shipped to providers subjected to CHANGE depending on the available weekly threshold amounts.
- Orders with less than min quantity will be rejected in OSIIS with a note that County Health Department (CHD) will fulfill the order and get in touch with the provider via email or phone.
  - Example of the message: "Your order will be fulfilled by your County Health Department. Watch for e-mail communication about the process and phone calls to arrange vaccine transfer."
  - CHDs will deliver vaccines to providers on the same or the following week. Delivered by CHD employees, national guard, or courier service.

# **Ordering Process**

- Upon delivery of vaccine by CHD, the provider should complete 4 steps:
  - 1. Sign a Bill of Lading and keep a copy.
  - 2. Check that delivered vaccines are viable.
  - 3. Immediately place vaccines into storage according to <u>the guidelines</u> and label appropriately indicating expiration and/or Beyond-use dates (BUDs).
  - 4. Accept transfer in OSIIS.
- Questions about orders:
  - OSIIS: OSIISHELP@health.ok.gov
  - Vaccine ordering process: VaccineHelp@health.ok.gov
  - Order fulfillment/delivery: Contact CHDs (contacts will be shared in the follow-up email).




# **OSIIS Updates**

# Martin Lansdale, MPH OSIIS Data Quality Coordinator



# **Updating Passwords in OSIIS**







#### Request User Account

NOTICE: You are about to gain access to an Oklahoma State Department of Health application. By proceeding, you are agreeing that all information made available to you through this application will be kept confidential. Any unauthorized access, use, and/or disclosure of information received by you through this application is a violation of federal and state law and will result in a loss of access privileges, an action for civil damages, an action for civil charges, and/or disciplinary action including, but not limited to, suspension or dismissal. This release of protected health information is pursuant to an individual request as authorized under 45 C.F.R. § 164.524, 63 O.S. § 1-502.2, and/or other federal and state statutes, rules, and regulations.

Public Portal- If you need a shot record, please use the OSIIS Public Portal to download a copy of your record.

NOTICE: To access OSIIS as a provider or clinic, all new providers/clinics have to sign an Authorized Site Agreement (ASA). Click on the following link to complete the ASA: OSIIS Authorized Site Agreement



# **Shot Records: Public Portal**

- OSIIS has a public portal that can be found at the below link:
  - <u>https://osiis.health.ok.gov/osiis\_public/Application/PublicPortal</u>
  - **DISCLAIMER:** Not all shots are recorded in OSIIS as reporting private vaccine is not required.
- Patients can search and download a copy of their shot record for just covid shots or their complete immunization history through the portal.
- The public portal uses **patient name, date-of-birth, email, and phone number** for verification purposes (all have to be on the shot record in OSIIS or patients cannot pull their shot record).
- Currently OSIIS has a high amount of missing emails/phone numbers.
- Providers need to make sure to document email and phone number for the patient <u>and</u> <u>add/send it to OSIIS</u> with the shot record in order to increase the likelihood of a records match in the portal.



# News

WELCOME TO THE

#### **Oklahoma State Immunization Information System**

#### Default Provider/Clinic

Provider/Clinic : TEST PROVIDER ONE, TEST PROVIDER ONE

SELECT A CLINIC BY TYPING PROVIDER, CLINIC, VFC PIN, OR CLINIC CODE

#### News

[09/28/2022] - Update: Pediatric Bivalent Vaccine Formulations Pediatric Bivalent Vaccines

- Applications for Pfizer and Moderna Pediatric Bivalent products are currently under consideration.
  - Pfizer: Children aged 5 11 years. NDC (59267-0565-02)
  - Moderna: Children aged 6 17 years. More information will be released as it becomes available.
- Pending potential FDA EUA for the new Pediatric bivalent COVID-19 boosters, CDC's Advisory Committee on Immunization Practices (ACIP) will convene to discuss potential recommendations.
  - Once scheduled, ACIP meeting information is announced on the CDC website.
- Both vaccines are expected to be approved for children who have already completed a primary series.
- Children will be eligible to receive a single bivalent Pfizer of Moderna booster if they received either of the following products:
  - Pfizer Adult Vaccine (children aged 12 17)
  - Moderna Vaccine (Children aged 12 17)
  - Pfizer Pediatric Vaccine (Children aged 5 11)

#### Pfizer Pediatric Bivalent

- For children aged 5 11
- New product with a new NDC



A

×

# **Moderna Booster in OSIIS**

### Administer

Vaccination Time HH:MM AM/PM (HH:M	M A/P)	
	Administered By *	Refusal Reason *
Vaccine	TEST, TRAIN () 🗸	✓
COVID-19 mRNA (MOD)	TEST, TRAIN () 🗸	Mfg   Lot   Exp Date (MM/DD/YY)   Funding Src   Inv Loc   NDC   Brand *
		(I) MOD   TEST1   04/21/22   PAN   IITSTESTING2   80777-0273-99   MODERNA 🗸
	Did not Admin 🗌	Body Site * Route * Dosage Refusal Reason
	Delete	LD V INTRAMUSCULAR V 025
	VFC: Not VFC	
	Eligible	



# **How To Guides**

"How To" Guides

- Moderna Booster OSIIS Guide
- How to Turn On User Default Order Notifications
- Inventory Reconciliation
- How to Place a Covid-19 Vaccine Order
- Immunizing a Patient for COVID
- How to add an extra dose
- <u>Wastage</u>



# **Reducing Vaccine Errors**

Lauren Speer, BSN, RN. Immunization & Communicable Disease Nurse Consultant, Nursing Services



04/07/2023

# Reducing Vaccine Errors

Lauren Speer BSN, RN Immunization & Communicable Disease Nurse Consultant, Nursing Services



OKLAHOMA State Department of Health

# **OBJECTIVES**

- Vaccine errors and causes
- Ways to reduce vaccine errors
- What to do if you make a vaccine error



## **Most Frequent Vaccine Errors**

- 1. Wrong vaccine
- 2. Wrong age for vaccine
- 3. Wrong vaccine dose
- 4. Wrong vaccine interval
- 5. Improperly stored vaccine

### **Causes/Challenges of Vaccine Errors**

Distractions- busy clinic

Changes in recommendations

Easily misidentified products

Staff Training- turn over


Delayed vaccine schedules

# Reducing Vaccine Errors



## **Content** Rights of Vaccine Administration

- 1. Right patient
- 2. Right time
- 3. Right vaccine and diluent








## **Cont. Rights of Vaccine Administration**

- 4. Right dose
- 5. Right route, needle length, and technique



Injection Site and Needle Size		
Subcutaneous (Subcut) injection Use a 23–25 gauge needle. Choose the injection site that is appropriate to the person's age and body mass.		
AGE	NEEDLE LENGTH	INJECTION SITE
Infants (1-12 mos)	%"	Fatty tissue over antero-lateral thigh muscle
Children 12 mos or older, adolescents, and adults	%"	Fatty tissue over antero-lateral thigh muscle or fatty tissue over triceps
Intramuscular (IM) injection Use a 22-25 gauge needle. Choose the injection site and needle length that is appropriate to the person's age and body mass.		
AGE	NEEDLE LENGTH	INJECTION SITE
Newborns (1st 28 days)	5% <sup>1</sup> "	Anterolateral thigh muscle
Infants (1-12 mos)	1"	Anterolateral thigh muscle
Toddlers (1-2 yrs)	1-1¼"	Anterolateral thigh muscle <sup>3</sup>
	5 <sup>4</sup> -1"	Deltoid muscle of arm
Children (3-10 yrs)	% <sup>2</sup> -1"	Deltoid muscle of arm <sup>3</sup>
	1-1¼"	Anterolateral thigh muscle
Adolescents and teens (11-18 yrs)	5 <sup>42</sup> -1"	Deltoid muscle of arm <sup>3</sup>
	1-1½"	Anterolateral thigh muscle
Adults 19 yrs or older		
Female or male <130 lbs	% <sup>2</sup> -1"	Deltoid muscle of arm
Female or male 130–152 lbs	1"	Deltoid muscle of arm
Female 153-200 lbs Male 153-260 lbs	1-1%"	Deltoid muscle of arm
Female more than 200 lbs Male more than 260 lbs	1%"	Deltoid muscle of arm
Female or male, any weight	1 <sup>2</sup> -1½"	Anterolateral thigh muscle



Oklahoma State Immunization Information System

## **Other Ways to Reduce Vaccine Errors**

- Label your vaccines and separate vaccines into bins/trays when preparing vaccines.
- Store look-alike vaccines in different areas of the storage unit.
- Establish a "Do Not Disturb" or no interruption area or times when vaccines are being prepared.
- Triple-check work before administering or ask another staff member to check. (Double/triple checking what Accuvax has dispensed)
- Keep updated reference material posted in your work area.
- Clearly identify correct diluents for the correct vaccine.

- Integrate vaccine administration, storage and handling training.
- Rotate vaccine so that the earliest expiring vaccine is used first and remove expired vaccines/ diluents as soon as possible.
- Isolate vaccines exposed to improper temperatures and report.
- Create procedures to obtain a complete vaccine history and review OSIIS for history.
- Be familiar on where to find reference information esp. catch-up guidance.
- Educate families on the importance of routine vaccine schedule.

What to do if a vaccine error has occurred?





✤ Notify your supervisor.

- Fill out an incident report and email it to designated persons.
- File an online VAERS report at <u>https://vaers.hhs.gov/reportevent.html</u>
- ✤ Determine the cause of the error.
- Determine how to prevent the error from occurring again.
- Determine if the patient needs revaccination and at which interval.
- Notify the client or parent/guardian of incident and recommendations.

### Resources

- <u>https://www.immunize.org/askexperts/</u>
- https://www.cdc.gov/vaccines/schedules/index.html
- https://www.cdc.gov/vaccines/pubs/pinkbook/index.html

### References

- <u>https://www.cdc.gov/vaccines/hcp/admin/downloads/vaccine-administration-preventing-errors.pdf</u>
- <u>https://www.cdc.gov/vaccinesafety/hcproviders/reportingadverseevents.html</u>
- <u>Technically Speaking: Preventing Preventable Vaccine Administration Errors in Your Medical</u> <u>Setting | Children's Hospital of Philadelphia (chop.edu)</u>

# **Questions?**

Thank you!





# **Questions/Suggestions**

Looking Forward: Next Call June 2nd, 2023 at 12pm



Resources: Medical Updates & Immunization Site Training for All Healthcare Providers led by Pfizer Vaccines US Medical Affairs

Goal: Educate providers and immunization staff personnel on the proper use of the Pfizer-BioNTech COVID-19 Vaccines To access dates and links for upcoming training sessions, please visit\*:

https://www.pfizermedicalinformation.com/en-us/medical-updates



## Resources

#### **Testing:**

- Nasopharyngeal, throat, saliva
- <u>Testing@health.ok.gov</u>

#### Monoclonal Antibodies: (Amanda Cavner)

- <u>Antivirals@health.ok.gov</u>
- <u>https://oklahoma.gov/covid19/what-you-should-know/monoclonal-antibody-therapies.html</u>

#### Vaccine:

- <u>COVID-19 Vaccines | FDA</u>
- PREP Act Guidance
- Interim Clinical Considerations for Use of <u>COVID-19 Vaccines | CDC</u>
- COVID-19 Vaccination for Children | CDC
   Oklahoma State Department of Ha

- Pfizer: <u>Home (cvdvaccine-us.com)</u>
- Moderna: <u>What is Moderna COVID-19</u> <u>Vaccine (EUA)? | How Does It Work?</u> <u>(modernatx.com)</u>
- J&J: <u>Resources for COVID-19 Vaccine</u> <u>Education | Johnson & Johnson (jnj.com)</u>
- Novavax: <u>https://us.novavaxcovidvaccine.c</u> <u>om/hcp</u>

## **Resources/Tools**

OSIIS Training: <a href="https://osiis.health.ok.gov/osiis/Application/ApplicationHelp/Index">https://osiis.health.ok.gov/osiis/Application/ApplicationHelp/Index</a>





Vaccine Inventory Adjustment: On-Hand Expired Vaccines

- When reconciling inventory, check that your facility has no expired inventory on hand.
  - Navigate to the Vaccine Inventory On-Handscreen by selecting:
    - Inventory > Vaccines > On-Hand from the left-hand menu.
- Change the Status from On-Hand to Depleted/Expired
- Locate the Filter tab
- Locate the vaccine inventory item requiring an inventory adjustment.
- Click the corresponding Action button and select Adjustment.
  - Complete the following required fields:
  - Date (enter the actual date on which the inventory was wasted)
  - Reason (select Vtrcks Other)
  - **Modification** (if a value does not default, select Add or Subtract to make the corresponding adjustment)
  - Doses Adjusted (enter the number of doses wasted for the selected reason)
  - Comments (Expired)
- Click the Create button.
- Click the **On-Hand** menu item to return to the *Vaccine Inventory On-Hand* screen where you can verify the inventory was adjusted correctly.
- See attached video on Resources/Tools

## **QAs From Live Call**

